Prognosis of APL cases stratified by CD95 −1377 genotype
| Outcome . | CD95 −1377 status, events/patients* (%) . | Unadjusted OR/HR (95% CI); P . | Adjusted OR/HR (95% CI); P . | |
|---|---|---|---|---|
| GG . | GA + AA . | |||
| Failure to achieve complete remission | 14/187 (7) | 9/44 (20) | 4.22 (1.41-12.6); .01 | 4.31 (1.40-13.26); .007 |
| Death within 7 d | 5/187 (3) | 3/44 (7) | 3.39 (0.58-20.0); .18 | 2.00 (0.34-11.68); .4 |
| Death within 30 d | 11/187 (6) | 9/44 (20) | 6.02 (1.93-18.7); .002 | 4.82 (1.85-12.55); .0004 |
| Death within 8 wk | 11/187 (6) | 10/44 (23) | 7.26 (2.39-22.9); .0005 | 5.53 (2.19-13.97); .0001 |
| 5-year OS | 46/187 (79) | 17/44 (64) | 2.14 (1.10-4.15); .03 | 2.21 (1.22-4.00); .007 |
| 5-year RFS | 41/173 (79) | 13/35 (66) | 1.92 (0.92-4.02); .10 | 1.92 (1.27-2.90); .03 |
| Death from infection | 12/187 (7) | 8/44 (21) | 5.26 (1.63-16.99); .01 | 4.63 (1.79-11.99); .0006 |
| Outcome . | CD95 −1377 status, events/patients* (%) . | Unadjusted OR/HR (95% CI); P . | Adjusted OR/HR (95% CI); P . | |
|---|---|---|---|---|
| GG . | GA + AA . | |||
| Failure to achieve complete remission | 14/187 (7) | 9/44 (20) | 4.22 (1.41-12.6); .01 | 4.31 (1.40-13.26); .007 |
| Death within 7 d | 5/187 (3) | 3/44 (7) | 3.39 (0.58-20.0); .18 | 2.00 (0.34-11.68); .4 |
| Death within 30 d | 11/187 (6) | 9/44 (20) | 6.02 (1.93-18.7); .002 | 4.82 (1.85-12.55); .0004 |
| Death within 8 wk | 11/187 (6) | 10/44 (23) | 7.26 (2.39-22.9); .0005 | 5.53 (2.19-13.97); .0001 |
| 5-year OS | 46/187 (79) | 17/44 (64) | 2.14 (1.10-4.15); .03 | 2.21 (1.22-4.00); .007 |
| 5-year RFS | 41/173 (79) | 13/35 (66) | 1.92 (0.92-4.02); .10 | 1.92 (1.27-2.90); .03 |
| Death from infection | 12/187 (7) | 8/44 (21) | 5.26 (1.63-16.99); .01 | 4.63 (1.79-11.99); .0006 |
Events refers to failure to achieve CR, deaths, relapse, or infection-related death, depending on the analysis.